40
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Chemosensitivity of TEL-AML1 Fusion Transcript Positive Acute Lymphoblastic Leukemia Cells

, , &
Pages 615-623 | Received 25 Aug 2000, Published online: 01 Jul 2009
 

Abstract

The TEL-AML1 fusion which results from a cryptic t(12;21) translocation is the most frequently occurring genetic abnormality in childhood acute lymphoblastic leukemia (ALL) and has been associated with an excellent treatment outcome. In the present study, we examined the FAS/BCL-2 expression profiles and chemosensitivity of primary leukemic cells from children with newly diagnosed t(12;21)TEL-AML1 fusion transcript-positive versus t(12;21)TEL-AML1 fusion transcript-negative standard risk ALL. TEL-AML1+ ALL cells expressed higher levels of the pro-apoptotic protein Fas and lower levels of the anti-apoptotic protein Bcl2 than TEL-AML1 ALL cells, as determined by confocal laser scanning microscopy. TEL-AML1+ ALL cells were more sensitive to the apoptosis-inducing effects of serum deprivation, dexamethasone and vincristine than TEL-AML1 ALL cells. This study provides novel mechanistic insights regarding the chemosensitivity of TEL-AML1+ ALL cells and provides a cogent explanation for the excellent leukemia-free survival outcome of children with TEL-AML1+ ALL treated on contemporary chemotherapy programs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.